| Literature DB >> 32939414 |
Narmada Ashok1,2, Richard Kirubakaran3, Radha Saraswathy4.
Abstract
INTRODUCTION: The association of Vitamin D and children with asthma is known and there are several individual studies on Vitamin D polymorphisms. However, systematic reviews on all vitamin D associated gene polymorphisms have not been done in children with asthma.Entities:
Keywords: Asthma in children; Biotechnology; Genetics; Single nucleotide polymorphisms; Vitamin D associated gene polymorphisms
Year: 2020 PMID: 32939414 PMCID: PMC7479342 DOI: 10.1016/j.heliyon.2020.e04795
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1PRISMA diagram of the search done [20].
Demographic details extracted from the studies included in the analysis.
| S No | Studies | Year of pub | Country & Ethnicity | Population | Type of study | Method | Unit analyzed | HWE tested | No of cases | Mean age | No of controls | Mean age of controls | Matching bet case &Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Einisman et al [ | 2015 | Chile | Hospital based | Case control | PCR | Genotype | Not specified | 75 | 9.1yr (6 -15y) | 227 | 10.3 (2–12 yr) | Yes |
| 2 | Fawzy et al [ | 2018 | Egypt | Hospital | Case control | RT PCR analysis | Genotype | Yes | 96 | 10 | 96 | 7–14 yrs | yes |
| 3 | Hou et al [ | 2017 | China | Hospital | Case control | PCR- RFLP | SNP | Not specified | 70 | 8.84 +/- 3.21 | 70 | 8.04+/- 3.01 | yes |
| 4 | Hutchinson et al [ | 2018 | Ireland | Hospital | Case control | RFLP | Genotype | Yes | 44 | 8.7 | 55 | Mean age not mentioned | no |
| 5 | Iordanidou et al [ | 2014 | Greece | Hospital | Case control | PCR | Gene | Yes | 127 | 8.4+/- 0.2 | 91 | 9.6+/- 1.04 | Yes |
| 6 | Ismail et al [ | 2013 | Egypt | Hospital Based | Case control | PCR RFLP | SNP | No | 51 | 8.6 | 33 | 7.8 | Yes |
| 7 | Leung et al [ | 2015 | Hongkong | Hospital | Case control | Taqmann (PCR amplification) | SNP | Yes | 914 | 11+/- 0.4 | 1231 | 13.7 +/- 4.5 | Yes |
| 8 | Kilic et al [ | 2019 | Turkish | Hospital | Case control | RFLP | SNP | YES | 100 | 9.5+/- 2.8 | 80 | 9.5+/-2.5 | YES |
| 9 | Maalmi et al [ | 2013 | Tunisia | Population | Case control | PCR RFLP | Genotype | Yes | 155 | 9.1 (4 16yrs) | 225 | 9.5 (2–16yrs) | Yes |
| 10 | Munkhbayarlakh et al - Taiwan [ | 2019 | Taiwan | Hospital | Case control | PCR amplification (MassARRAY) | SNP | Yes | 94 | 7.77+/- 4.09 | 129 | 28.11+/- 9.67 | no |
| 11 | Munkhbayarlakh et al - Mongolian [ | 2019 | Mongolian | Hospital | Case control | PCR Amplification (MassARRAY) | SNP | Yes | 115 | 11.94+/- 10.28 | 256 | 27.75+/- 13.16 | No |
| 12 | Nabih et al [ | 2014 | Egypt | Community | Case control | PCR | Genotype | Yes | 180 | 7.98+/-3.22 | 180 | 8.5+/- 2.22 | YES |
| 13 | NavasNazario et al [ | 2015 | Yale | Community | Case control | PCR | Genotype | Yes | 81 | 5.8 | 247 | 5.6 | Yes |
| 14 | Papadopoulou et al [ | 2015 | Cypriot | Community | Case control | PCR | Genotype allele | Yes | 190 | 16.9 (16–18year) | 671 | 17 (16–18yrs) | yes |
| 15 | Pillai et al [ | 2011 | America | Hospital | Case control | PCR | SNP | Yes | 139 | 11.2 (6-17y) | 74 | 11.8 (6-17y) | Yes |
| 16 | Santos et al [ | 2018 | Brazil | Hospital | Observational, Case control | PCR | Promoter region | Not specified | 60 | 8.7+/-2.5 | 17 | 10.8 = /- 2.2 | yes |
| Studies based on family based analysis of transmission | |||||||||||||
| 1 | Bosse et al [ | 2009 | Canada | Family Based | FBAT | PCR | SNP | Yes | 1064 probands 210 | 17.6 | Not specified | 48.3 | No |
| 2 | Poon et al [ | 2004 | Quebec | Community | FBAT | FBAT | Genes &SNP | Yes | 570 subjects 223 probands | 16 (2–46yrs) | 569 | 48 (3-96y) | Not matched |
| 3 | Raby et al [ | 2004 | America | Community | FBAT | FBAT | Genes | Yes | 1041 children 582 complete family | Girls 8.2 y boys 8.1 y | Not mentioned | 30 -55y | NO |
| 4 | Wjst et al [ | 2006 | Germany | Population | Family based | PCR RFLP | Genotype | Yes | 210 families | 13.6 | 131 | Among families | No |
| 5 | Volmert et al [ | 2004 | Germany | Community | FBAT | PCR | SNP | Not specified | 176 families with 352 parents 411 children | 10.7+/- 3.8 | 11.5+/- 4.3 | Yes | |
(Abbreviation foot note - HWE – Hardy-Weinberg Equilibrium, PCR – Polymerase chain reaction, RFLP – Restriction Fragment Length Polymorphism, FBAT – Family Based Analysis of transmission, SNP- Single nucleotide polymorphism, RT – Reverse transcriptase).
Quality Score of the studies included.
| Criteria/Studies | Representativeness of cases | Source of controls | Ascertainment of asthma | Sample size | Quality control of genotyping methods | Hardy-Weinberg equilibrium (HWE) | Total score |
|---|---|---|---|---|---|---|---|
| Einisman et al [ | 1 | 0.5 | 1 | 1 | 0 | 0 | 3.5 |
| Fawzy et al [ | 1 | 1.5 | 2 | 0 | 1 | 1 | 6.5 |
| Hou et al [ | 1 | 1.5 | 2 | 0 | 0 | 0 | 3.5 |
| Hutchinson et al [ | 1 | 1.5 | 2 | 0 | 0 | 1 | 5.5 |
| Iordanidou et al [ | 1 | 1.5 | 2 | 1 | 0 | 1 | 7 |
| Ismail et al [ | 1 | 1 | 2 | 0 | 1 | 0 | 5 |
| Leung et al [ | 1 | 1.5 | 2 | 2 | 0 | 1 | 7.5 |
| Kilic et al [ | 1 | 1.5 | 2 | 0 | 0 | 1 | 5.5 |
| Maalmi et al [ | 1 | 1.5 | 2 | 1 | 0 | 1 | 6.5 |
| Munkhbayarlakh et al [ | 1 | 1.5 | 2 | 1 | 0 | 1 | 6.5 |
| Nabih et al [ | 1 | 2 | 2 | 0 | 0.5 | 1 | 6.5 |
| NavasNazario et al [ | 1 | 2 | 1 | 1 | 0 | 1 | 6 |
| Papadopoulou et al [ | 2 | 2 | 2 | 1 | 0.5 | 1 | 8.5 |
| Pillai et al [ | 1 | 1.5 | 2 | 0 | 0.5 | 1 | 6 |
| Santos et al [ | 1 | 1.5 | 2 | 0 | 0 | 0 | 4.5 |
| Studies based on family based analysis of transmission | |||||||
| Bosse et al [ | 2 | 2 | 2 | 2 | 1 | 1 | 9 |
| Poon et al [ | 2 | 0 | 2 | 2 | 0.5 | 1 | 7.5 |
| Raby et al [ | 2 | 2 | 2 | 2 | 1 | 1 | 10 |
| Wjst et al [ | 1 | 2 | 2 | 1 | 0.5 | 1 | 7.5 |
| Vollmert et al [ | 2 | 2 | 2 | 1 | 1 | 0.5 | 8 |
Figure 2Funnel plot analysis for publication bias.
Figure 3Forest Plot analysis of Apa 1 polymorphism.
Results of the tests of association for the VDR gene polymorphisms.
| SNP | TYPE | NO. OF STUDIES | TEST OF ASSOCIATION | TEST OF HETEROGENEITY | |
|---|---|---|---|---|---|
| OR (95% CI) | P | I2 | |||
| Apa (overall) | Allele Major | 7 | 0.81 (0.71,0.91) | 0.381 | 6.1% |
| Allele minor | 7 | 1.21 (1.07,1,37) | 0.350 | 10.3% | |
| Homozygous major | 11 | 0.83 (0.70,0.98) | 0.011 | 56.2% | |
| Heterozygous | 11 | 1.08 (0.93,1.25) | 0.000 | 88.3% | |
| Homozygous minor | 11 | 0.91 (0.77,1.09) | 0.000 | 91.4% | |
| Apa (European) | Allele Major | 4 | 0.74 (0.60,0.92) | 0.174 | 39.6% |
| Allele minor | 4 | 1.34 (1.08,1.65) | 0.159 | 42.1% | |
| Homozygous major | 4 | 0.79 (0.57,1.09) | 0.031 | 56.1% | |
| Heterozygous | 4 | 1.36 (1.01,1.82) | 0.754 | 0.0% | |
| Homozygous minor | 4 | 0.84 (0.57,1.22) | 0.008 | 74.4% | |
| Apa (American) | Allele Major | 2 | 0.82 (0.70,0.96) | 0.0% | 0.863 |
| Allele minor | 2 | 1.18 (1.00,1.39) | 0.0% | 0.989 | |
| Homozygous major | 3 | 0.81 (0.64,1.02) | 0.0% | 0.968 | |
| Heterozygous | 3 | 0.92 (0.74,1.14) | 0.0% | 0.652 | |
| Homozygous minor | 3 | 1.37 (1.04,1.80) | 0.0% | 0.902 | |
| Apa (Africans) | Allele Major | 1 | 0.95 (0.67,1.34) | ||
| Allele minor | 1 | 1.06 (0.74,1.50) | |||
| Homozygous major | 1 | 0.85 (0.56,1.30) | |||
| Heterozygous | 1 | 1.29 (0.84,1.98) | |||
| Homozygous minor | 1 | 0.46 (0.17,1.25) | |||
| Apa (Asians) | Allele Major | 0 | |||
| Allele minor | 0 | ||||
| Homozygous major | 3 | 1.17 (0.59,2.33) | 0.001 | 85.1% | |
| Heterozygous | 3 | 1.07 (0.76,1.51) | 0.000 | 97.5% | |
| Homozygous minor | 3 | 0.61 (0.44,0.83) | 0.000 | 97.7% | |
| Bsm1 (overall) | Allele (major) | 3 | 1.10 (0.90.1.34) | 0.177 | 42.3% |
| Allele (minor) | 3 | 0.91 (0.75,1,11) | 0.177 | 42.3% | |
| Homozygous major | 6 | 1.25 (0.87,1.74) | 0.038 | 60.7% | |
| Heterozygous | 6 | 1.35 (1.07,1.71) | 0.000 | 84% | |
| Homozygous minor | 3 | 1.35 (1.07,1.71) | 0.000 | ||
| Bsm1 (European) | Allele (major) | 2 | 0.93 (0.71,1.22) | 0.656 | 0.0% |
| Allele (minor) | 2 | 1.07 (0.82,1.40) | 0.656 | 0.0% | |
| Homozygous major | 2 | 0.77 (0.48,1.26) | 0.732 | 0.0% | |
| Heterozygous | 2 | 1.18 (0.81,1.72) | 0.251 | 24.2% | |
| Homozygous minor | 2 | 0.98 (0.06,1.47) | 0.338 | 0.0% | |
| Bsm1 (African) | Allele (major) | 1 | 1.34 (1.00,1.80) | ||
| Allele (minor) | 1 | 0.74 (0.55,1.00) | |||
| Homozygous major | 1 | 2.15 (1.23,3.76) | |||
| Heterozygous | 1 | 0.77 (0.51,1.16) | |||
| Homozygous minor | 1 | 0.84 (0.54,1.29) | |||
| Bsm1 (Asians) | Allele (major) | 0 | |||
| Allele (minor) | 0 | ||||
| Homozygous major | 3 | 2.07 (0.46,9.21) | 0.038 | 60.7% | |
| Heterozygous | 3 | 3.36 (2.12,5.32) | 0.003 | 83.3% | |
| Homozygous minor | 3 | 4.40 (3.18,6.09) | 0.000 | 98% | |
| Taq 1 (overall) | Allele (major) | 7 | 1.22 (1.08,1.38) | 0.000 | 76.1% |
| Allele (minor) | 7 | 1.13 (1.01,1.27) | 0.001 | 72.7% | |
| Homozygous major | 10 | 0.99 (0.86,1.14) | 0.000 | 95% | |
| Heterozygous | 10 | 1.08 (0.93,1.26) | 0.000 | 75.1% | |
| Homozygous minor | 10 | 0.73 (0.58,0.92) | 0.001 | 70.1% | |
| Taq 1 (European) | Allele (major) | 4 | 0.99 (0.80,1.23) | 0.031 | 66.2% |
| Allele (minor) | 4 | 1.01 (0.82,1.25) | 0.031 | 66.2% | |
| Homozygous major | 4 | 0.92 (0.68,1.24) | 0.060 | 59.4% | |
| Heterozygous | 4 | 1.17 (0.87,1.56) | 0.918 | 0.0% | |
| Homozygous minor | 4 | 0.87 (0.58,1.31) | 0.001 | 53% | |
| Taq 1 (American) | Allele (major) | 2 | 1.35 (1.14,1.59) | 0.001 | 90.8% |
| Allele (minor) | 2 | 1.35 (1.15,1.59) | 0.666 | 0.0% | |
| Homozygous major | 3 | 1.22 (0.98,1.52) | 0.002 | 83.4% | |
| Heterozygous | 3 | 0.98 (0.79,1.22) | 0.0 | 0.918 | |
| Homozygous minor | 3 | 0.77 (0.58,1.06) | 0.292 | 18.9% | |
| Taq 1 (Africans) | Allele (major) | 1 | 1.32 (0.98,1.78) | ||
| Allele (minor) | 1 | 0.78 (0.56,1.02) | |||
| Homozygous major | 1 | 1.14 (0.74,1.74) | |||
| Heterozygous | 1 | 1.349 (0.89,2.03) | |||
| Homozygous minor | 1 | 0.43 (0.23,0.80) | |||
| Taq 1 (Asians) | Allele (major) | 0 | |||
| Allele (minor) | 0 | ||||
| Homozygous major | 2 | 0.68 (0.51,0.92) | 0.000 | 99.4% | |
| Heterozygous | 2 | 1.08 (0.57,2.03) | 0.000 | 93.8% | |
| Homozygous minor | 2 | EXCLUDED | |||
| Fok 1 (overall) | Allele (major) | 6 | 1.34 (1.17,1.52) | 0.000 | 92% |
| Allele (minor) | 6 | 0.89 (0.78,1.02) | 0.052 | 54.3% | |
| Homozygous major | 10 | 0.96 (0.80,1.16) | 0.000 | 90.7% | |
| Heterozygous | 10 | 0.99 (0.85,1.14) | 0.000 | 90.2% | |
| Homozygous minor | 10 | 1.07 (0.90,1.27) | 0.000 | 86.3% | |
| Fok 1 (European) | Allele (major) | 2 | 1.32 (0.96,1.81) | 0.547 | 0.0% |
| Allele (minor) | 2 | 0.76 (0.55,1.04) | 0.547 | 0.0% | |
| Homozygous major | 2 | 1.61 (0.98,2.64) | 0.782 | 0.0% | |
| Heterozygous | 2 | 0.82 (0.55,1.23) | 0.650 | 0.0% | |
| Homozygous minor | 2 | 0.93 (0.55,1.54) | 0.233 | 29.6% | |
| Fok 1 (American) | Allele (major) | 2 | 0.94 (0.80,1.11) | 0.540 | 0.0% |
| Allele (minor) | 2 | 0.93 (0.79,1.10) | 0.237 | 28.3% | |
| Homozygous major | 3 | 0.94 (0.67,1.32) | 0.622 | 0.0% | |
| Heterozygous | 3 | 0.95 (0.76,1.18) | 0.280 | 21.5% | |
| Homozygous minor | 3 | 0.89 (0.70,1.12) | 0.888 | 0.0% | |
| Fok1 (Africans) | Allele (major) | 2 | 3.54 (2.66,4.72) | 0.379 | 0.0% |
| Allele (minor) | 2 | 0.89 (0.66,1.20) | |||
| Homozygous major | 2 | 2.79 (1.90,4.09) | 0.648 | 0.0% | |
| Heterozygous | 2 | 1.46 (0.98,2.16) | 0.388 | 0.0% | |
| Homozygous minor | 2 | 0.67 (0.32,1.42) | |||
| Fok1 (Asians) | Allele (major) | 0 | |||
| Allele (minor) | 0 | ||||
| Homozygous major | 2 | 0.44 (0.26,0.75) | 0.000 | 96% | |
| Heterozygous | 2 | 0.61 (0.42,0.88) | 0.000 | 98.6% | |
| Homozygous minor | 2 | 1.45 (0.94,2,23) | 0.000 | 97.2% | |
| Fok1 (Egyptian) | Allele (major) | 0 | |||
| Allele (minor) | 0 | ||||
| Homozygous major | 1 | 0.28 (0.17,0.44) | |||
| Heterozygous | 1 | 1.75 (1.14,2.68) | |||
| Homozygous minor | 1 | 2.32 (1.40,3.83) |
Figure 4Forest analysis of Bsm 1 polymorphism.
Figure 5Forest plot analysis of Taq 1 polymorphism.
Figure 6Forest plot analysis of Fok 1 polymorphism.
SNPs analyzed in various studies in Vitamin D associated genes that had significant association with children with asthma.
| Gene analysed | No of studies | Name of the study | SNP analysed | Type of analysis | Significance (p value) |
|---|---|---|---|---|---|
| 2 | Leung et al [ | rs645163 | Logistic regression | Significant (p-0.018) | |
| Bosse et al [ | rs4674338 | FBAT | No association | ||
| 5 | Bosse et al [ | rs11023774 | FBAT | Significant (p -0.017) | |
| Pillai et al [ | rs10766197 | Homozygous minor | Significant (p-0.044) | ||
| Wjst et al [ | Several SNPs | Case control | Transmission present | ||
| Leung et al [ | Several SNP | Case control | No association | ||
| Nazario et al [ | Several SNP | Details not known | No association | ||
| 3 | Leung et al [ | rs1048691 | Logistic regression & additive model | Significant (p-0.041) | |
| Wjst et al [ | rs238532, rs2072052, | FBAT | No association | ||
| Bosse et al [ | FBAT | No association | |||
| 3 | Bosse et al [ | rs8124792 | FBAT | Significant (p - 0.030) | |
| Wjst et al [ | rs2244719 | Transmission significance | No significance | ||
| Pillai et al [ | Case control | Associated with decreased asthma control | |||
| Ismail et al [ | rs282679 | Case control | Significant OR 2.68 (1.36,5.28) | ||
| Leung et al [ | rs2282679 | Case control | Not significant | ||
| Wjst et al [ | rs222040 | FBAT | 0,0163 | ||
| Nazario et al [ | rs 7041 | Wild type allele | Significant association (p < 0.001 | ||
| Fawzy et al [ | rs 7041 | Allelic | 3.08 (2.03,4.69) p < 0.0001 | ||
| Bosse et al [ | 2 SNP | Was not included in analysis |
Abbreviation – SNP – Single nucleotide polymorphism, FBAT – Family Based analysis of transmission. The polymorphisms given in bold has been analysed & documented by several authors whereas those not in bold have been analysed only by that author.